FDA approves generic cancer treatment for 2026 availability
The FDA has approved a generic version of lenalidomide, a drug used to treat multiple myeloma and myelodysplastic syndromes, with availability set for Jan. 31, 2026.
The FDA has approved a generic version of lenalidomide, a drug used to treat multiple myeloma and myelodysplastic syndromes, with availability set for Jan. 31, 2026.
